Vascular Intervention Position

Discussion in 'Biotronik' started by anonymous, Sep 13, 2018 at 4:15 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Hello -

    I'm interviewing for this position. I don't have any experience in this area. How contract driven is this space?

    Who are the big players? Does BioTronik have some sort of niche in this area? Or will this be a non-starter?

    Also - what's the company culture like?

    Thanks!
     

  2. anonymous

    anonymous Guest

    All depends on the area
     
  3. anonymous

    anonymous Guest

    It would be the Pacific NW
     
  4. anonymous

    anonymous Guest

    HahahjahahahahahahahahahahqhahaHahahahahahahahahahahahahahahahahah
     
  5. anonymous

    anonymous Guest

    Other than the person laughing and not contributing - is there someone who might be able to make an honest attempt at answering the OP? I, too, am curious about BioTronik and the Vascular Intervention position.

    Who are the players to be looking out for? Is this basically dominated by contracts/GPO's only? Any other info would be truly appreciated.

    Thanks in advance...
     
  6. anonymous

    anonymous Guest

    Any info?
     
  7. anonymous

    anonymous Guest

    Crickets? Really? Can I just get an honest answer?
     
  8. anonymous

    anonymous Guest

    Is anyone else interviewing for this spot?

    Who is on contract? Abbot? Medtronic? BSC?
     
  9. anonymous

    anonymous Guest

    Biotronik has a full line of peripheral balloons .014,.018 and .035 as well as self expanding SFA and Iliac stents. There products were distributed the past two years by the vascular sales team at Getinge. The products are good but not really clinically superior to Medtronic, Boston, Abbott etc... They do have a tiny nich spot with their SFA stent in that it is the only SFA indicated stent available in a 4mm diameter.

    The products were on all GPO contract through Getinge but will not be on contract when Biotronik sells direct. The peripheral Stent/Balloon market is very contract driven with Medtronic, Boston, Abbott controlling most of those contracts due to leverage with athrectomy etc....

    Biotronik has a tiny (less than 5%, US) market share in CRM that coupled with the fact that vascular surgeons in most places are doing the bulk of peripheral work will not give Biotronik the a leg up in pull through products due to CRM presence

    Personally what I see in peripherals is athrectomy/laser used in majority of cases with stents used as bailout, dissections etc..... Due to that Biotronik will have a tough time getting shelf space for stents and honestly balloons are becoming a commodity product bundled in with athrectomy etc... or going to the lowest bidder
     
  10. anonymous

    anonymous Guest

    Thank you for the great feedback! Really appreciate it.

    This position will be launching their new Orsiro absorbable drug eluting stent. Supposedly has better data outcomes than the competition, costs less, and is pending approval, which they think is coming Jan 1.